Moderna, Inc. (MRNA)
Moderna's work developing seasonal vaccines is ‘risky' under current FDA, analyst says
The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development.
Wall Street Breakfast Podcast: Amazon Adds BETA To Cart
Amazon (AMZN) acquires a 5.3% stake in BETA Technologies, sharply boosting BETA's premarket share price. Moderna (MRNA) faces an FDA refusal-to-file for its mRNA-1010 influenza vaccine, citing inadequate trial controls but no safety or efficacy issues.
Moderna shares fall after FDA refuses to review new flu vaccine
Moderna shares opened 14% lower in Frankfurt on Wednesday in low volume after the U.S. Food and Drug Administration refused to review the company's approval application for its influenza vaccine.
Moderna says FDA refuses to review its application for experimental flu shot
The Food and Drug Administration refused to start a review of Moderna's application for its experimental flu shot, the company said. It's another sign of the Trump administration's influence on tightening vaccine regulation in the U.S.
The FDA has refused to review Moderna's application to sell a new flu shot, the latest move by the administration against vaccines
The company said the agency wouldn't review its application on the grounds that the study testing the shot wasn't sufficient.
Moderna (MRNA) Laps the Stock Market: Here's Why
In the latest trading session, Moderna (MRNA) closed at $41.95, marking a +2.29% move from the previous day.
Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock?
MRNA is set to report Q4 results on Feb. 13, with expectations for an earnings beat as COVID vaccine sales and pipeline updates stay in focus.
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Moderna (MRNA) concluded the recent trading session at $42.55, signifying a -3.45% move from its prior day's close.
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi and Pfizer, targeting ~$500m annual revenues by 2030, with a forward P/S of ~3x and P/E of ~7.5x. MRNA's growth depends on COVID/flu combo vaccine, intismeran cancer program, and RSV vaccine, but faces higher risk due to elevated spending and lack of major partners.
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Moderna (MRNA) closed the most recent trading day at $47.99, moving 1.48% from the previous trading session.
